Development of a cell viability assay to assess drug metabolite structure–toxicity relationships

Development of a cell viability assay to assess drug metabolite structure–toxicity relationships CYP2C9-Mediated Metabolic Activation of Losartan Detected by a Highly Sensitive Cell-Based Screening Assay Mechanism-Based Inactivation (MBI) of Cytochrome P450 Enzymes: Structure–Activity Relationships and Discovery Strategies To Mitigate Drug–Drug Interaction Risks Overcoming Time-Dependent Inhibition (TDI) of Cytochrome P450 3A4 (CYP3A4) Resulting from Bioactivation of a Fluoropyrimidine Moiety Cytochrome P450 Enzymes Mechanism Based Inhibitors: Common Sub-Structures and Reactivity Homology modeling and molecular dynamics of CYP1A1 and CYP2B1 to explore the metabolism of aryl derivatives by docking and experimental assays Metabolic activation enhances the cytotoxicity, genotoxicity and mutagenicity of two synthetic alkaloids with selective effects against human tumour cell lines Preclinical Strategy to Reduce Clinical Hepatotoxicity Using in Vitro Bioactivation Data for >200 Compounds Use of Simple Docking Methods To Screen a Virtual Library for Heteroactivators of Cytochrome P450 2C9 Development of an In-Capillary Approach to Nanoscale Automated in Vitro Cytochromes P450 Assays